Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.
2015
Disclosure JT, EC, DM, AAM, KLG, RAR, AOJ-L, EAO and YBM are current or former employees of Merck & Co, Inc., Whitehouse Station, NJ, USA, and may own stock and/or hold stock options in the company. HEB has received research grants as investigator and honoraria as a consultant and has served on advisory board and speaker’s bureau for Merck & Co, Inc. EAB has received research grants and honoraria from Merck & Co, Inc.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
27
References
4
Citations
NaN
KQI